Early results from REFLECTION, a real-world study, mirrored results for Grail Inc.'s multi-cancer early detection (MCED) assay in clinical trials, according to a presentation at the 2024 Early ...
Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination ...
Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...
Sandoz, Eli Lilly, Bayer, and Genentech executives tell what strikes them about the 2024 presidential race — and how the ...
Be Biopharma has raised $82m in financing to advance a gene therapy targeting hemophilia B to a Phase I/II trial, whilst also ...
Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback